| Mon, Jul 21, 2008 | | • | Biovest Announces Conference Call / Webcast to Discuss Phase 3 BiovaxID(R) Anti-Cancer Vaccine Results
Business Wire (Mon, Jul 21)
| | Thu, Jul 17, 2008 | | • | Biovest Reports Results for Patients Treated with Anti-Cancer Vaccine: BiovaxID(R) Demonstrates Clinically and Statistically Significant Improvement of Disease-Free Survival in Non-Hodgkin's Lymphoma in Pivotal Phase 3 Clinical Trial
Business Wire (Thu, Jul 17)
| | Mon, Jul 14, 2008 | | • | ACCENTIA BIOPHARMACEUTICALS INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statemen
EDGAR Online (Mon, Jul 14)
| | Mon, Jun 23, 2008 | | • | Accentia Biopharmaceuticals to Present at the Jefferies Second Annual Healthcare Conference
Business Wire (Mon, Jun 23)
| | Fri, Jun 20, 2008 | | • | ACCENTIA BIOPHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct
EDGAR Online (Fri, Jun 20)
| | • | Biovest Misleading in BioVaxID Data
at Minyanville.com (Fri, Jun 20)
| | Thu, Jun 19, 2008 | | • | Accentia Biopharmaceutical's Multiple Sclerosis Breakthrough
at Seeking Alpha (Thu, Jun 19)
| | Wed, Jun 18, 2008 | | • | ACCENTIA BIOPHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct
EDGAR Online (Wed, Jun 18)
| | Tue, Jun 17, 2008 | | • | Accentia Biopharmaceuticals gets backing for key products
at bizjournals.com (Tue, Jun 17)
| | • | Accentia Reports on Multiple Sclerosis Study: Revimmune(R) Shows Unprecedented Results in Reducing Disability and Improving Functions
Business Wire (Tue, Jun 17)
| | • | Accentia Biopharmaceuticals Announces $8.5 Million Financing to Advance Key Strategies for SinuNase(TM) and Revimmune(TM)
Business Wire (Tue, Jun 17)
| | Wed, Jun 11, 2008 | | • | ACCENTIA BIOPHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
EDGAR Online (Wed, Jun 11)
| | • | Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms
Business Wire (Wed, Jun 11)
| | Thu, Jun 5, 2008 | | • | ACCENTIA BIOPHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct
EDGAR Online (Thu, Jun 5)
| | Thu, May 29, 2008 | | • | ACCENTIA BIOPHARMACEUTICALS INC Financials
EDGAR Online Financials (Thu, May 29)
| | Fri, May 23, 2008 | | • | Accentia Biopharmaceuticals transfers stock listing
at bizjournals.com (Fri, May 23)
| | • | ACCENTIA BIOPHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rul
EDGAR Online (Fri, May 23)
| | • | Accentia Transfers Listing to NASDAQ Capital Market
Business Wire (Fri, May 23)
| | Fri, May 16, 2008 | | • | Accentia Biopharmaceutical loss widens
at bizjournals.com (Fri, May 16)
| | • | Accentia Biopharmaceuticals Reports Fiscal Second Quarter Financial Results
Business Wire (Fri, May 16)
|
Add ABPI News to My Yahoo!:
 
| |
|
0.25% Nasdaq 
Headlines
